Recent News for EDIT - Editas Medicine, Inc.

Date Title
Aug 12 Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors
Aug 9 Edited Transcript of EDIT earnings conference call or presentation 6-Aug-19 9:00pm GMT
Aug 8 Bayer buys Cambridge cell therapy startup BlueRock at $1B value
Aug 8 Editas Medicine, Inc. (EDIT) Q2 2019 Earnings Call Transcript
Aug 7 Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
Aug 7 Editas Medicine Remains on Track
Aug 7 Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q2 2019 Results - Earnings Call Transcript
Aug 6 Editas Medicine (EDIT) Reports Q2 Loss, Lags Revenue Estimates
Aug 6 New chief at Editas
Aug 6 Editas Medicine EPS misses by $0.06, misses on revenue
Aug 6 Editas Medicine Announces Second Quarter 2019 Results and Update
Aug 6 The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
Aug 5 Editas Medicine Q2 2019 Earnings Preview
Aug 1 Legal fight over Broad Institute's patent for CRISPR gene editing flares up again
Jul 31 Is Intellia Therapeutics a Buy?
Jul 30 Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update
Jul 29 Editas Medicine (EDIT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Jul 25 Editas launches first in-human study of CRISPR gene therapy for rare eye disorder
Jul 25 Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10
Jul 23 CRISPR Could Change Medicine, But Not in the Way Wall Street Expects
Jul 10 Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June
Jul 8 The Science Of Biotech Investing With Bhavneesh Sharma (Podcast)
Jul 7 Is Editas Medicine a Buy?
Jul 5 Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
Jul 4 What Kind Of Shareholders Own Editas Medicine, Inc. (NASDAQ:EDIT)?
Back to the Main EDIT Page...